President gets sweeping power to block tech exports to China—with minimal congressional oversight
H.R. 1122 — China Technology Transfer Control Act of 2025 · Filed by Mark Green (R-TN) · Introduced Feb 7, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill authorizes the President to block exports of sensitive U.S. technology and intellectual property to China—including AI, semiconductors, biotech, and military-relevant innovations—and to sanction foreign companies and Chinese entities that violate these controls. It also requires the U.S. Trade Representative to maintain an annual list of Chinese products receiving government support under China's 'Made in China 2025' industrial policy, potentially triggering trade restrictions on those goods.
Why we flagged it
The bill's core mechanism is dual: (1) executive authority to control exports of sensitive tech to China under IEEPA, and (2) creation of a government-maintained list of Chinese products receiving state support, with implied trade consequences. It is fundamentally a national-security and trade-policy instrument, not a commemorative, appropriations, or narrow tax measure.
What the text implies
- The bill grants the President unilateral power to designate 'covered national interest technology' without requiring congressional approval of each designation, creating a de facto executive veto over private-sector technology transfers with minimal transparency.
- Sanctions under IEEPA are triggered by 'knowing' conduct (actual or constructive knowledge), which may expose U.S. companies and their foreign subsidiaries to liability for transactions they did not directly authorize, creating compliance uncertainty.
The full analysis lists 5 implications of this text.
Who stands to gain
U.S. semiconductor manufacturers (Intel, Qualcomm, Broadcom); U.S. defense contractors (Lockheed Martin, Raytheon, General Dynamics); U.S. biotech and pharmaceutical companies